ClinicalTrials.gg
CompletedNCT01710020Updated Dec 18, 2012Results posted

Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

A Phase 1 interventional study of CP-690,550 in End-Stage Renal Disease and Hemodialysis, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-12-18.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Kidney Failure, Chronic by Pfizer — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Pfizer.

Enrollment
9th of 10
12 · median 161
Started
2003
the only one that year
Phase 1
4 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Kidney Failure, Chronic by Pfizer, this one is the 9th largest by enrollment, is the only one that started in 2003, is one of 4 in phase 1, and was the 8th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 10 studies in Kidney Failure, Chronic by Pfizer is open now. The open studies under Kidney Failure, Chronic, anywhere →

Where they have run

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Kidney Failure, Chronic by Pfizer as a file.
02

Study summary

There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis. If significant non-renal clearance of the drug occurred such that dialyzability of CP-690,550 could not be assessed in Period 1, a second period (Period 2) will be conducted. In Period 2, a single dose of drug will be administered approximately 4 hours prior to hemodialysis.

03

Conditions studied

  • End-Stage Renal Disease
  • Hemodialysis

Keywords

  • CP-690
  • 550
  • pharmacokinetics
  • end-stage renal disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with end-stage renal disease
  • Subjects need hemodialysis 3 times weekly

Exclusion criteria

Exclusion Criteria:

  • Subjects with evidence or history of disease, excluding those common for subjects with End-Stage Renal Disease (ESRD).
  • Subjects with any condition possibly affecting drug absorption.
  • Subjects with with the exception of adequately treated basal cell carcinoma of the skin.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    CP-690,550

    Drug: CP-690,550

Interventions

  • CP-690,550 10 mg oral powder for constitution

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hours (hrs) post-dose in Period 1

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1

  3. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1

  5. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1

  6. Oral Clearance (CLpo)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing given dose of drug with AUC.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1

  7. Dialyser Clearance (CL HD) From 0 to 1 Hour

    Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided (/) by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

    Time frame: 0 to 1 hrs during hemodialysis started 4 hrs post-dose in Period 2

  8. Dialyser Clearance (CL HD) From 1 to 2 Hour

    Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

    Time frame: 1 to 2 hrs during hemodialysis started 4 hrs post-dose in Period 2

  9. Dialyser Clearance (CL HD) From 2 to 3 Hour

    Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

    Time frame: 2 to 3 hrs during hemodialysis started 4 hrs post-dose in Period 2

  10. Dialyser Clearance (CL HD) From 3 to 4 Hour

    Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

    Time frame: 3 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2

Secondary outcomes

  1. Fraction of Unbound Drug (fu)

    Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.

    Time frame: 2 hours post-dose in Period 1

Other outcomes

  1. Overall Dialyser Clearance (CL HD)

    Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

    Time frame: 0 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2

  2. Dialyser Clearance (CL HD) From 3 to 3.5 Hour

    Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

    Time frame: 3 to 3.5 hrs during hemodialysis started 4 hrs post-dose in Period 2

07

Results

Posted Dec 18, 2012

Participant flow

Period 1
Participant flow — Period 1
MilestoneCP-690,550 (10 mg OPC)
Started12
Completed11
Not completed1
Withdrew: Protocol violation1
Washout Period (at Least 14 Days)
Participant flow — Washout Period (at Least 14 Days)
MilestoneCP-690,550 (10 mg OPC)
Started11
Completed11
Not completed0
Period 2
Participant flow — Period 2
MilestoneCP-690,550 (10 mg OPC)
Started11
Completed11
Not completed0

Outcome measures

PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hours (hrs) post-dose in Period 1
Reported as:
Mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
nanogram*hour/milliliter (ng*hr/mL)CP-690,550 (Period 1)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]396 ± 158
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
ng*hr/mLCP-690,550 (Period 1)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)385 ± 151
PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1
Reported as:
Mean · nanogram/milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax)
nanogram/milliliter (ng/mL)CP-690,550 (Period 1)
Maximum Observed Plasma Concentration (Cmax)106 ± 23.9
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrCP-690,550 (Period 1)
Time to Reach Maximum Observed Plasma Concentration (Tmax)0.5 (0.5 to 0.5)
PrimaryPlasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1
Reported as:
Mean · hr
Plasma Decay Half-Life (t1/2)
hrCP-690,550 (Period 1)
Plasma Decay Half-Life (t1/2)3.46 ± 1.18
PrimaryOral Clearance (CLpo)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It was calculated by dividing given dose of drug with AUC.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8, 12, 16, 24 hrs post-dose in Period 1
Reported as:
Mean · milliliter/minute (mL/min)
Oral Clearance (CLpo)
milliliter/minute (mL/min)CP-690,550 (Period 1)
Oral Clearance (CLpo)501 ± 243
PrimaryDialyser Clearance (CL HD) From 0 to 1 Hour

Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided (/) by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

Time frame:
0 to 1 hrs during hemodialysis started 4 hrs post-dose in Period 2
Reported as:
Mean · mL/min
Dialyser Clearance (CL HD) From 0 to 1 Hour
mL/minCP-690,550 (Period 2)
Dialyser Clearance (CL HD) From 0 to 1 Hour311 ± 124
PrimaryDialyser Clearance (CL HD) From 1 to 2 Hour

Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

Time frame:
1 to 2 hrs during hemodialysis started 4 hrs post-dose in Period 2
Reported as:
Mean · mL/min
Dialyser Clearance (CL HD) From 1 to 2 Hour
mL/minCP-690,550 (Period 2)
Dialyser Clearance (CL HD) From 1 to 2 Hour325 ± 138
PrimaryDialyser Clearance (CL HD) From 2 to 3 Hour

Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

Time frame:
2 to 3 hrs during hemodialysis started 4 hrs post-dose in Period 2
Reported as:
Mean · mL/min
Dialyser Clearance (CL HD) From 2 to 3 Hour
mL/minCP-690,550 (Period 2)
Dialyser Clearance (CL HD) From 2 to 3 Hour332 ± 135
PrimaryDialyser Clearance (CL HD) From 3 to 4 Hour

Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

Time frame:
3 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2
Reported as:
Mean · mL/min
Dialyser Clearance (CL HD) From 3 to 4 Hour
mL/minCP-690,550 (Period 2)
Dialyser Clearance (CL HD) From 3 to 4 Hour292 ± 111
SecondaryFraction of Unbound Drug (fu)

Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration.

Time frame:
2 hours post-dose in Period 1
Reported as:
Mean · ratio
Fraction of Unbound Drug (fu)
ratioCP-690,550 (Period 1)
Fraction of Unbound Drug (fu)0.390 ± 0.042
Other pre-specifiedOverall Dialyser Clearance (CL HD)

Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

Time frame:
0 to 4 hrs during hemodialysis started 4 hrs post-dose in Period 2
Reported as:
Mean · mL/min
Overall Dialyser Clearance (CL HD)
mL/minCP-690,550 (Period 2)
Overall Dialyser Clearance (CL HD)318 ± 132
Other pre-specifiedDialyser Clearance (CL HD) From 3 to 3.5 Hour

Dialyser clearance was calculated as amount of drug in dialysate collected over a period of time (AHD) divided by the product of fraction unbound of drug in plasma (fu), corresponding mid-time plasma concentration of drug (Cmid), and duration of dialysate collection period (tm). CL HD = AHD/(fu\*Cmid\*tm).

Time frame:
3 to 3.5 hrs during hemodialysis started 4 hrs post-dose in Period 2
Reported as:
Mean · mL/min
Dialyser Clearance (CL HD) From 3 to 3.5 Hour
mL/minCP-690,550 (Period 2)
Dialyser Clearance (CL HD) From 3 to 3.5 Hour377 ± 200

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CP-690,550 (Period 1)—0/12 (0%)5/12 (41.7%)
CP-690,550 (Period 2)—0/11 (0%)4/11 (36.4%)
Most frequent other events
Most frequent other events
EventCP-690,550 (Period 1)CP-690,550 (Period 2)
HeadacheGeneral disorders2/120/11
DyspepsiaGastrointestinal disorders0/121/11
EcchymosisBlood and lymphatic system disorders0/121/11
HypoglycemiaMetabolism and nutrition disorders1/121/11
DizzinessNervous system disorders0/121/11
ParesthesiaNervous system disorders0/121/11
Cough increasedRespiratory, thoracic and mediastinal disorders1/121/11
Respiratory tract infectionRespiratory, thoracic and mediastinal disorders0/121/11
PainGeneral disorders1/120/11
ThrombocytopeniaBlood and lymphatic system disorders1/120/11

Baseline characteristics

Age Continuous
Age Continuous(years)Entire Study Population
Mean45.9 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female2
Male10
08

Study locations

2 sites
  • Pfizer Investigational Site
    Orlando, Florida 32806, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55404, United States
09

References and documents

Publications

  • Krishnaswami S, Chow V, Boy M, Wang C, Chan G. Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J Clin Pharmacol. 2014 Jan;54(1):46-52. doi: 10.1002/jcph.178. Epub 2013 Sep 30. PubMed 24030917 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Jun 2003 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 9 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 18, 2012
Start
Feb 2003
Primary completionActual
Jun 2003
CompletionActual
Jun 2003
Results first posted
Dec 18, 2012
Last update
Dec 18, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01710020
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Feb 2003
Primary completion
Jun 2003
Completion
Jun 2003
Results posted
Dec 18, 2012
Last update
Dec 18, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion